

DORSET MEDICINES ADVISORY GROUP

Recommendation Summary



**Dorset
Clinical Commissioning Group**

The Dorset Medicines Advisory Group (DMAG) includes representatives from the four provider Trusts, Public Health Dorset and GPs within the Clinical Commissioning Group (CCG). It advises the system on prescribing and commissioning of medicines in Dorset.

Summary of recommendations made by the group 15th September 2020. Formulary entries and associated documents can be accessed at www.dorsetformulary.nhs.uk.

PRODUCT	DECISION		COMMENTS
1. Products re-categorised	Previous position	Recommended position	
Lurasidone	Non-Formulary Black	Red	Audit to be reviewed after 12 months, on the number of patients who were started, the number of patients who discontinued, data around weight gain, and whether its off-patent price has reduced
Osvaren®	Red	Amber	In accordance with the phosphate binders shared care guideline (below)
2. New requests			
N/A			
3. Products considered by NICE			
Dupilumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) TA648			
4. Miscellaneous recommendations by DMAG			
Wording ' Restricted use: High Strength preparations. See BNF	Removal of wording from the pancreatin entry on the formulary (01.09.04)		

PRODUCT	DECISION	COMMENTS
<p><u>advice</u> for advice regarding high strength preparations (e.g. Pancrease HL[®], Nutrizym 22[®], Creon 25000[®])</p>		
<p>5. Further Assessment / Evidence Required</p>		
<p>N/A</p>		
<p>6. New documents approved</p>		
<p>The Pathways for the Evaluation of Drugs in Dorset The DMAG Workplan 20/21 Pancreatic Enzyme Replacement Therapy (A guide to taking) In-Focus Pancreatic enzyme replacement therapy The Diabetes Foot wound care formulary and antimicrobial management Shared Care Guideline for the use of phosphate binders in the management of hyperphosphataemia in patients with chronic kidney disease</p>		
<p>7. Documents Reviewed</p>		
<p>Working Group ToR Shared care guideline for prescribing rifaximin (Targaxan[®]) for preventing episodes of overt hepatic encephalopathy in adult patients Commissioning statement for Rifaximin (TARGAXAN[®]) for preventing episodes of overt hepatic encephalopathy in adult patients PPI deprescribing algorithm (adults) from PrescQIPP Management of hypomagnesaemia in primary care guideline Commissioning statement For Prucalopride in the treatment of Chronic idiopathic constipation</p>		

PRODUCT	DECISION	COMMENTS
		<p>Commissioning statement on the use of infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy</p> <p>Commissioning statement for ustekinumab for Crohn's Disease</p>

Classification of products:

'RED' drugs for hospital use only

'AMBER with shared care' drugs suitable for use on specialist advice with shared care arrangements

'AMBER' drugs suitable for use on specialist advice without shared care arrangements

'GREEN' drugs suitable for prescribing in primary and secondary care

'Not Recommended' – drugs not recommended for use in Dorset